NCT03839446View on ClinicalTrials.gov

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

February 2, 2023

Study Completion Date

December 22, 2024

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

mitoxantrone + etoposide + gemtuzumab ozogamicin

10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Robert Redner, MD

OTHER